Anti-HIV drugs promote β-amyloid deposition and impair learning and memory in BALB/c mice

Acta Neuropsychiatr. 2020 Oct;32(5):257-264. doi: 10.1017/neu.2020.19. Epub 2020 May 7.

Abstract

Objectives: Growing evidence suggested that antiretroviral (ARV) drugs may promote amyloid beta (Aβ) accumulation in HIV-1-infected brain and the persistence of HIV-associated neurocognitive disorders (HANDs). It has also been shown that lipid peroxidation upregulates β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) expression and subsequently promotes Aβ peptide production. In the present study, we examined whether chronic exposure to the anti-HIV drugs tenofovir disoproxil fumarate (TDF) and nevirapine induces lipid peroxidation thereby promoting BACE1 and Aβ generation and consequently impair cognitive function in mice.

Methods: TDF or nevirapine was orally administered to female BALB/c mice once a day for 8 weeks. On the 7th week of treatment, spatial learning and memory were assessed using the Morris water maze test. The levels of lipid peroxidation, BACE1, amyloid β 1-42 (Aβ1-42) and Aβ deposits were measured in the hippocampal tissue upon completion of treatment.

Results: Chronic administration of nevirapine induced spatial learning and memory impairment in the Morris water maze test, whereas TDF did not have an effect. TDF and nevirapine administration increased hippocampal lipid peroxidation and Aβ1-42 concentration. Nevirapine further upregulated BACE1 expression and Aβ deposits.

Conclusion: Our results suggest that chronic exposure to TDF and nevirapine contributes to hippocampal lipid peroxidation and Aβ accumulation, respectively, as well as spatial learning and memory deficits in mice even in the absence of HIV infection. These findings further support a possible link between ARV drug toxicity, Aβ accumulation and the persistence of HANDs.

Keywords: HIV-associated cognitive motor complex; amyloid; beta-secretase; oxidative stress; reverse transcriptase inhibitors.

MeSH terms

  • AIDS Dementia Complex / chemically induced*
  • Administration, Oral
  • Amyloid Precursor Protein Secretases / drug effects
  • Amyloid Precursor Protein Secretases / metabolism
  • Amyloid beta-Peptides / drug effects*
  • Amyloid beta-Peptides / metabolism
  • Amyloid beta-Protein Precursor / drug effects
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / toxicity
  • Aspartic Acid Endopeptidases / drug effects
  • Aspartic Acid Endopeptidases / metabolism
  • Brain / drug effects
  • Brain / metabolism
  • Brain / virology
  • Cognitive Dysfunction / chemically induced
  • Disease Models, Animal
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / isolation & purification
  • Hippocampus / metabolism
  • Learning Disabilities / chemically induced*
  • Lipid Peroxidation / drug effects
  • Maze Learning / drug effects
  • Memory / drug effects*
  • Mice
  • Mice, Inbred BALB C
  • Nevirapine / adverse effects
  • Nevirapine / pharmacology
  • Nevirapine / toxicity
  • Tenofovir / adverse effects
  • Tenofovir / pharmacology
  • Tenofovir / toxicity

Substances

  • APP protein, human
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Anti-HIV Agents
  • Nevirapine
  • Tenofovir
  • Amyloid Precursor Protein Secretases
  • Aspartic Acid Endopeptidases
  • BACE1 protein, human